Skip to content

Our
Technologies

External and implantable neuromodulation platforms built to deliver ARC Therapy™

All ONWARD® Medical therapies are investigational and not available for commercial use.

Meet David Mzee and learn about his journey

Learn more

Our Mission

Driven to restore
Movement
Function
Independence
in people with spinal cord injury

Discover Our Therapy

  • ARC Therapy is targeted stimulation of the spinal cord designed to restore upper and lower limb movement and other functions, such as blood pressure regulation, after SCI.

    Our external ARCEX® System is built to non-invasively deliver ARCEX Therapy, and our implantable ARCIM® and ARCBCI™ Systems are built to minimally invasively deliver ARCIM Therapy.

    These benefits have been observed in published pre-clinical and human feasibility studies.


    Clinical results may vary.
    Investigational and not available for commercial use.

    Watch how it works

External Platform

  • Investigational, spinal cord stimulation platform to non-invasively deliver targeted ARCEX Therapy to the spinal cord.

    The US FDA granted the ARCEX platform Breakthrough Device Designations for improvement of upper and lower limb function, bladder control, regulation of blood pressure, and alleviation of spasticity in people with spinal cord injury.

    Learn more

Implantable Platform

  • Investigational, neurostimulation platform to minimally invasively deliver targeted ARCIM Therapy to the spinal cord.

    The US FDA awarded the ARCIM platform Breakthrough Device Designations for restoration of leg motor function, blood pressure regulation, trunk stabilization, bladder control, and alleviation of spasticity in people with spinal cord injury.

    Learn more

Implantable Platform

  • Investigational system that pairs ARCIM Therapy with a brain-computer interface (BCI) to restore thought-driven movement of the upper and lower limbs.

    In partnership with EPFL and CEA-Clinatec, in 2021 we successfully implanted an investigational BCI in a human to augment our ARCIM Therapy with thought-driven movement of the legs after paralysis. The approach was published in Nature in May 2023.

    With a European Innovation Council grant to study restoration of thought-driven arm and hand movement after SCI, an additional human was implanted with ARCIM Therapy + BCI in 2023. Three more people are scheduled to participate in the study in 2024.

    Learn more

Read Our Publications

    Learn more

    Contact Us

    Please fill out the form
    if you would like to contact
    us or receive updates

    Complete form
    All ONWARD® Medical devices and therapies referenced here, including but not limited to ARCIM®, ARCEX®, ARCBCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.